Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)
Information source: St. Justine's Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infection
Intervention: Piperacillin-tazobactam (Drug)
Phase: Phase 1
Status: Not yet recruiting
Sponsored by: St. Justine's Hospital Official(s) and/or principal investigator(s):
Julie Autmizguine, MD, MHS, Principal Investigator, Affiliation: St. Justine's Hospital
Overall contact:
Julie Autmizguine, MD, MHS, Phone: 1 514-345-4931, Email: julie.autmizguine@umontreal.ca
Summary
Severe infection is one of the main causes of disease in hospitalized children and can be
deadly. With the lack of novel antibiotics approved in children and the emergence of drug
resistant bacteria, there is a critical need to optimize dosing of existing antibiotics.
Piperacillin-tazobactam is an antibiotic frequently used for treatment of severe infection
in children in Canadian hospitals. To optimize this antibiotic's efficacy despite the rise
of antibiotic resistance, alternative dosing strategy is commonly used in adults, which
consists of prolonging the time during which the drug is infused (4 hours instead of 30
min). Children clear piperacillin-tazobactam from their bodies at a slower rate than adults,
consequently extended-infusion strategy cannot be directly extrapolated from adult to
children. We believe that younger children need piperacillin-tazobactam infusions that are
shorter compared to adults to achieve appropriate concentrations.
Clinical Details
Official title: Safety and Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Infants and Children
Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Evaluation of Clearance (CL) for piperacillin and tazobactamProportion of subjects who achieve Pharmacodynamic target (at least 50% of free plasma piperacillin concentration above the MIC [50% fT > MIC]) Evaluation of Volume of distribution (V) for piperacillin and tazobactam
Secondary outcome: Proportion of subjects experiencing adverse events (AEs)
Detailed description:
This is a prospective, open-label Pharmacokinetics and safety study of
piperacillin-tazobactam in children 2 months-6y of age.
Overall goal: To establish extended-infusion piperacillin-tazobactam dosing recommendations
in infants and young children with normal renal function, for the treatment of sepsis due to
resistant organisms. Dosing recommendations will be provided according to different levels
of antibiotic resistance (MIC). We aim to establish the age threshold below which extended
infusion does not provide additional therapeutic benefit because of immature renal function.
We also aim to describe the PK of piperacillin-tazobactam standard dosing in children with
acute kidney injury.
Study population #1: Normal Renal Function:
Evaluate the PK of piperacillin-tazobactam extended infusion in children 2 months-6y with
normal renal function.
Hypothesis 1. 1 : Population clearance of piperacillin will be 20% lower in infants 2-5
months compared with infants 6-23 months and will reach adult values at 2 years of age.
Hypothesis 1. 2: Alternative dosing strategy used in this clinical trial will achieve
pharmacodynamics (PD) target (50% fT > MIC) for minimum inhibitory concentration (MIC) up to
16 mg/L in 90% of infants and children 2 months-6y.
Study Population #2: Acute Kidney Injury:
Describe the PK of piperacillin-tazobactam in children with kidney injury, using the
standard dosing.
Hypothesis 2. 1: Population clearance of piperacillin will be 15% lower in infants with
acute kidney injury but normal glomerular filtration rate (GFR). Clearance will increase as
GFR decreases.
Screening:
Infants and children will be screened using a pharmacy software application available in our
institution, displaying a list of all subjects meeting inclusion criteria in real time.
Recruitment will take place in units where children receive piperacillin-tazobactam.
Enrollment/Baseline: Baseline/Pre-Dose Assessment:
After it has been determined that the participant satisfies all inclusion and no exclusion
criteria and after the parent or legal guardian has signed the informed consent form,
subjects will be assigned a study number and the following evaluations will be recorded in
the clinical research form:
1. Participant demographics including gender, date of birth, chronologic age, corrected
age if <1 year of age and born <37 weeks of gestational age, race, birth weight if <1
year of age, and weight at time of consent.
2. Active clinical diagnoses
3. Concomitant medications taken in 72 hours prior to first dose of
piperacillin-tazobactam or during treatment with piperacillin-tazobactam
4. Laboratory and microbiologic determinations within 72 hours prior to first dose of
piperacillin-tazobactam
5. Microbiological results of sterile body fluids (blood, cerebrospinal fluid (CSF), urine
obtained by catheterization or supra-pubic tap), within 72 hours prior to the first
dose of study drug
Assessments/Procedures (Day 1 to Day 14): The following assessments will be conducted each
day while the patient is on study
1. Study medication administration: The date and time, amount, infusion duration and site
of administration of each dose will be recorded. Day 1 will be day of first dose of
study drug.
2. PK samples collection: date and time of sample collection, total blood volume
collected.
3. Laboratory determinations on each day of PK sample collection
4. Microbiological results of sterile body fluids (blood, CSF, urine obtained by
catheterization or supra-pubic tap)
5. Concomitant medications
6. AEs
Follow-up (Day 15 to 17 or End of Therapy): The following assessments will be conducted at
end of therapy:
1. Laboratory determinations on the last day of study drug, or within 72h after the last
study dose
2. AEs up to 72h after the last study dose
Laboratory Determinations:
Any labs obtained per standard of care may be recorded while the patient is on study at the
following timeline: 1) within 72 hours prior to the first dose of study medication 2) within
72h of PK sample collection 3) on Day 14 of therapy (or end of therapy, whichever comes
first), or within 72h hours of last study dose will be recorded. If multiple values for a
laboratory are obtained in the 72 hours prior to first dose, record the value closest to
enrollment.
1. Any hematology values including hemoglobin, hematocrit, white blood cell count,
platelet count, and differential.
2. Any serum chemistry values including blood urea nitrogen (BUN), serum creatinine,
potassium, sodium, Aspartate transaminase (AST), Alanine transaminase (ALT), albumin.
3. Given that renal function is the main determinant of piperacillin-tazobactam clearance,
serum creatinine will be obtained prior to the first study dose, even if not done per
standard of care.
Microbiological Determinations:
All results for any cultures obtained of sterile body fluids (blood, CSF, urine obtained by
catheterization or supra-pubic tap) from 72 hours prior to first piperacillin-tazobactam
dose through the final dose of piperacillin-tazobactam or Day 14 of therapy (whichever comes
first) will be recorded in the case report form (CRF).
Special Assays or Procedures: Pharmacokinetics (PK) Samples:
During study treatment, 4 plasma PK samples (200 µL of whole blood/sample) per subject will
be collected using an opportunistic approach; PK samples can be collected after any dose of
study drug because PK of piperacillin is linear. PK samples will be obtained at the same
time as laboratory tests collected per routine medical.
Specimen Preparation, Handling, and Shipping:
PK samples will be collected in ethylenediamine-tetra-acetic acid (EDTA) microcontainers and
processed immediately or placed on ice until processing. Samples will be identified using
preprinted labels with the protocol number. Plasma will be separated via centrifugation
(3000g for 10 minutes at 4°C), manually aspirated and transferred to polypropylene tubes.
Plasma samples will be frozen at - 80°C freezer until analysis.
Once enrollment and sample collection are completed, PK samples will be shipped on dry ice
to a central laboratory where piperacillin and tazobactam plasma concentrations will be
measured using a validated bioanalytical assay.
Eligibility
Minimum age: 2 Months.
Maximum age: 6 Years.
Gender(s): Both.
Criteria:
Study population #1: Normal renal function
Inclusion Criteria:
- Children 2 months - 6 years of age*
- Piperacillin-tazobactam indicated per standard of care
- Informed consent
Exclusion Criteria:
- Insufficient venous access to allow extended infusion
- History of anaphylaxis to β-lactams
- Supported with extracorporeal membrane oxygenation (ECMO)
- On renal replacement therapy
- Cystic fibrosis
- Acute Kidney injury
- Chronic renal insufficiency defined as defined as a glomerular filtration rate of
10-60 mL/min/1. 73 m2
Study population #2: Acute Kidney injury
Inclusion Criteria:
- Children 2 months - 6 years of age
- Piperacillin-tazobactam indicated per standard of care
- Informed consent
- Acute Kidney injury defined as the following:
- Doubling of serum creatinine according to upper limit of normal for age and
gender or
- Doubling of baseline serum creatinine (defined as the creatinine level at
admission, if the value is within normal limit for age and gender) We wil use
the smaller value of these 2 definitions to diagnose acute kidney injury in a
given subject.
Exclusion Criteria:
- History of anaphylaxis to β-lactams
- Supported with extracorporeal membrane oxygenation (ECMO)
- On renal replacement therapy
- Cystic fibrosis
- Chronic renal insufficiency defined as defined as a glomerular filtration rate of
10-60 mL/min/1. 73 m2
Locations and Contacts
Julie Autmizguine, MD, MHS, Phone: 1 514-345-4931, Email: julie.autmizguine@umontreal.ca
St. Justine's Hospital, Montreal, Quebec H3T 1C5, Canada; Not yet recruiting
Julie Autmizguine, MD, MHS, Phone: 514 345-4931, Ext: 5631, Email: julie.autmizguine@umontreal.ca
Mariana Dumitrascu, MD, Phone: 1514 345-4931, Ext: 6648, Email: mariana.dumitrascu@recherche-ste-justine.qc.ca
Catherine Litalien, MD, PhD, Sub-Investigator
Yves Théoret, B. Pharm., PhD, Sub-Investigator
Denis Lebel, B. Pharm., Sub-Investigator
Céline Thibault, MD, Sub-Investigator
Additional Information
Starting date: July 2015
Last updated: June 4, 2015
|
